
American investigators assigned 36 children randomly to oral FP or placebo for three months. Histological remission was observed significantly more frequently in the fluticasone group (50 vs 9%). Clinically, vomiting improved significantly in FP responders, but other clinical symptoms did not reach a significant improvement with FP treatment.39 Another American research group from Indianapolis treated 80 children with either FP or systemic corticosteroids and demonstrated a greater degree of histological improvement but no significant difference in clinical remission rates.40 In adult patients only case series have been published. The investigators treated 21 patients with 220 μg FP, swallowed twice a day for six weeks: all patients experienced symptomatic relief.41 Remedios et al. confirmed the symptomatic effectiveness of FP in 19 adult patients with concurrent significant histological improvement.28
Although topical corticosteroids have been proven to be effective, all studies, including a recently published prospective study,42 show a high relapse rate after stopping treatment (as in our case). This highlights the need for maintenance treatment. As long-term treatment is needed in EO, systemic corticosteroid use is precluded by its long-term side effects including cataract, growth retardation in children, osteoporosis and adrenal suppression. Using oral FP, these systemic effects can be minimised, thus enhancing compliance.28 Acute and severe exacerbations of EO, however, can still be treated with systemic corticosteroids.22
It must be noted that before high-dose inhaled FP can be fully implemented as maintenance treatment for EO it is important for future trials to further investigate the use of possible systemic side effects. And continuing evaluations of dose and duration of therapy are needed. Proposed mechanisms through which corticosteroids influence EO are inhibition of pro-inflammatory mediators, down-regulation of chemotactic factors and induction of apoptosis.9
Other proposed treatments are exclusion diets, elementary diets, gastric acid suppression, and stabilisers of eosinophilic trafficking and activation.
The selective elimination of foods with demonstrable allergic effects in the patient under consideration has been reported as an effective strategy in individual patients. In children, the use of an elemental diet has also been shown to be effective.14,43 However, the long-term implementation of such therapy is hampered by nutritional deprivation, psychological problems, unnecessary food aversion and loss of quality of life.
As mentioned earlier, a trial of high-dose proton pump inhibitor therapy is justified to exclude acid GERD as part of the differential diagnosis of EO, but as gastric acid plays no part in the pathogenesis of true EO, long-term treatment with proton-pomp inhibitors is not effective.6
Treatments that target eosinophilic trafficking and activation have been assessed in pilot studies. A case series using the leukotriene inhibitor montelukast showed symptomatic but no histological improvement and unfortunately a quick relapse after therapy cessation.44 Mepolizumab, a humanised monoclonal antibody directed against IL-5, was infused intravenously once a month in one patient with EO unresponsive to topical and oral steroid therapy. Mepolizumab produced symptomatic, endoscopic, and histological improvement.45 Following this initial success, ongoing placebo-controlled trials have been set up to further analyse the use of mepolizumab in EO. Therapies focussing at controlling a suggested allergy component of EO, using antihistamines and cromolyn – a mast cell stabiliser and also an inhibitor of eosinophil mediator release and T-cell function – showed limited success in case reports.13,46
Recently there have been promising results in case reports concerning the use of purine analogues – azathioprine (AZA) and 6-mercaptopurine – showing clinical and histological response. Two of the three studied patients experienced relapses after ceasing AZA therapy.47
Finally, EO, although chronic, does not appear to limit life expectancy and no associated oesophageal malignancies have ever been reported.6,48
CoNClUsioN
EO is a mucosal inflammatory disorder, most likely leading to oesophageal dysmotility with an unclear pathogenesis which is increasingly recognised in children but also in adults. The diagnosis should be considered in patients with unexplained dysphagia, especially when there are no or only subtle endoscopic abnormalities of the oesophagus. Histological biopsies of normal appearing mucosa throughout the length of the oesophagus are pivotal in establishing the diagnosis. Absence of endoscopic signs of GERD and a negative PPI trial of the oesophagus are prerequisites for making a definite diagnosis of EO. The use of FP aerosol is the most successful long-term treatment, with minimal side effects. With such treatment the long-term prognosis seems good.
rEfErENCEs
1. Dobbins JW, Sheahan D, Behar J. Eosinophilic gastroenteritis with
esophageal involvement. Gastroenterology.1977;72:1312-6.2. Sgouros SN, Bergele C, Mantides A. Eosinophilic esophagitis in adults:
a systematic review. Eur J Gastoenterol Hepatol. 2006;18:211-7.3. Prasad GA, Talley NJ, Romero Y, et al. Prevalence and predictive factors
of eosinophilic esophagitis in patients presenting with dysphagia: A prospective study. Am J Gastroenterol. 2007;102:2627-32.
Sprenger, et al. Eosinophilic oesophagitis: an enigmatic, emerging disease.
january 2009, Vol. 67, no. 1
Eosinophilic oesophagiti... 暂无评价 5页 免费 03 Bolus Transit-oesopha......Twenty-five of the 40 patients had macroscopical oesophagitis with ulcers or...
(J Clin Pediatr,2013,31(1):1-4) Key words : eosinophilic esophagitis; ...Eosinophilic oesophagitis: epidemiology, clinical aspects, association to allergy...
The presence of eosinophilic oesophagitis and motility abnormalities of the oesophago-gastric tract seem to have a limited clinical relevance. On the contrary...
?The value of endoscopy in patients with refractory GERD is very low— Eosinophilic oesophagitis was found in only 0.9% of RGERD patients,and NERD and...
胃食管返流性咳嗽(GERC) 嗜酸细胞性支气管炎(eosinophilic bronchitis,EB) ) ...Oesophagitis Stricture Barrett’s Carcinoma Reflux cough Reflux laryngitis Asthma...
胃食管返流性咳嗽(GERC) 嗜酸细胞性支气管炎(eosinophilic bronchitis,EB) ) ...Oesophagitis Stricture Barrett’s Carcinoma Reflux cough Reflux laryngitis Asthma...
热门文档